308.72
price down icon0.31%   -0.96
after-market After Hours: 308.72
loading
United Therapeutics Corp stock is traded at $308.72, with a volume of 326.01K. It is down -0.31% in the last 24 hours and up +5.43% over the past month. United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
See More
Previous Close:
$309.68
Open:
$308.25
24h Volume:
326.01K
Relative Volume:
0.65
Market Cap:
$13.93B
Revenue:
$2.99B
Net Income/Loss:
$1.21B
P/E Ratio:
12.32
EPS:
25.06
Net Cash Flow:
$1.13B
1W Performance:
+1.58%
1M Performance:
+5.43%
6M Performance:
-17.21%
1Y Performance:
+11.68%
1-Day Range:
Value
$306.16
$310.74
1-Week Range:
Value
$300.46
$311.99
52-Week Range:
Value
$264.33
$417.81

United Therapeutics Corp Stock (UTHR) Company Profile

Name
Name
United Therapeutics Corp
Name
Phone
(301) 608-9292
Name
Address
1000 SPRING ST, SILVER SPRING, MD
Name
Employee
1,305
Name
Twitter
Name
Next Earnings Date
2024-10-30
Name
Latest SEC Filings
Name
UTHR's Discussions on Twitter

Compare UTHR with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
308.72 13.71B 2.99B 1.21B 1.13B 25.06
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
11.06 48.05B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
161.97 71.39B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
RDHL
Redhill Biopharma Ltd Adr
1.85 3.20M 35.75M 11.57M -26.25M -3.8069
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.41 43.73B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.94 19.35B 16.54B -1.64B 749.00M -1.45

United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-25-25 Downgrade Wells Fargo Overweight → Equal Weight
Apr-21-25 Upgrade BofA Securities Underperform → Neutral
Jul-11-24 Downgrade Morgan Stanley Overweight → Equal-Weight
Feb-12-24 Upgrade Goldman Sell → Neutral
Feb-05-24 Initiated Leerink Partners Outperform
Dec-08-23 Initiated Wells Fargo Overweight
Dec-06-22 Initiated UBS Buy
Dec-05-22 Initiated Goldman Sell
Oct-11-22 Initiated Morgan Stanley Overweight
Sep-20-22 Reiterated BofA Securities Underperform
Sep-19-22 Resumed Wedbush Outperform
Feb-11-22 Initiated BTIG Research Neutral
Jul-14-21 Upgrade Argus Hold → Buy
Apr-26-21 Resumed Credit Suisse Outperform
Feb-01-21 Upgrade H.C. Wainwright Neutral → Buy
Sep-14-20 Resumed JP Morgan Overweight
Jun-25-20 Reiterated H.C. Wainwright Neutral
Mar-10-20 Upgrade Jefferies Hold → Buy
Feb-27-20 Upgrade Cowen Market Perform → Outperform
Jan-31-20 Upgrade JP Morgan Neutral → Overweight
Dec-03-19 Initiated BofA/Merrill Underperform
Aug-01-19 Upgrade Jefferies Underperform → Hold
Aug-01-19 Upgrade Ladenburg Thalmann Neutral → Buy
Jul-01-19 Upgrade Credit Suisse Neutral → Outperform
May-17-19 Upgrade UBS Sell → Neutral
May-09-19 Upgrade Credit Suisse Underperform → Neutral
Oct-12-18 Upgrade Standpoint Research Hold → Buy
Aug-08-18 Downgrade Credit Suisse Neutral → Underperform
Apr-03-18 Upgrade Credit Suisse Underperform → Neutral
Feb-22-18 Reiterated Barclays Underweight
Jan-18-18 Resumed Credit Suisse Underperform
Dec-27-17 Reiterated Wedbush Outperform
Apr-27-17 Reiterated Wedbush Outperform
Mar-30-17 Initiated UBS Sell
Mar-16-17 Initiated Credit Suisse Underperform
View All

United Therapeutics Corp Stock (UTHR) Latest News

pulisher
May 21, 2025

HHS layoffs create ‘clear opportunity’ for local health, life sciences companies to add talent - The Business Journals

May 21, 2025
pulisher
May 20, 2025

Liquidia Says UTC Can’t Stop Its New Lung Drug From Launching - Bloomberg Law News

May 20, 2025
pulisher
May 14, 2025

Stewartville pig-to-human transplant facility to be complete in 2026 - Post Bulletin

May 14, 2025
pulisher
May 14, 2025

Interesting UTHR Put And Call Options For July 18th - Nasdaq

May 14, 2025
pulisher
May 14, 2025

Q1 Therapeutics Earnings: United Therapeutics (NASDAQ:UTHR) Impresses - Yahoo Finance

May 14, 2025
pulisher
May 13, 2025

UTHR Q1 Earnings Call: Double-Digit Growth Continues, Pipeline Expansion Remains Central - Yahoo Finance

May 13, 2025
pulisher
May 12, 2025

UTC Again Seeks To Stave Off Lung Drug Competitor In IP Suit - Law360

May 12, 2025
pulisher
May 12, 2025

Liquidia Faces Patent Litigation Filed by United Therapeutics - marketscreener.com

May 12, 2025
pulisher
May 12, 2025

Liquidia (LQDA) Faces Patent Infringement Lawsuit from United Th - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Liquidia Says New Litigation Filed Against Co In U.S. - marketscreener.com

May 12, 2025
pulisher
May 12, 2025

Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics - Yahoo Finance

May 12, 2025
pulisher
May 11, 2025

Is United Therapeutics (UTHR) the Best Stock to Buy According to Jim Simons’ Renaissance Technologies? - Insider Monkey

May 11, 2025
pulisher
May 09, 2025

Liquidia Corp (LQDA) Q1 2025 Earnings Call Highlights: Strategic Advances and Legal Wins Propel ... - Yahoo Finance

May 09, 2025
pulisher
May 09, 2025

3 Big Reasons to Love United Therapeutics (UTHR) - Yahoo Finance

May 09, 2025
pulisher
May 08, 2025

MANNKIND CORP SEC 10-Q Report - TradingView

May 08, 2025
pulisher
May 08, 2025

Liquidia Corporation Reports First Quarter 2025 Financial Results and Provides Corporate Update - Yahoo Finance

May 08, 2025
pulisher
May 07, 2025

TD Cowen maintains United Therapeutics stock Buy rating By Investing.com - Investing.com Nigeria

May 07, 2025
pulisher
May 07, 2025

TD Cowen maintains United Therapeutics stock Buy rating - Investing.com

May 07, 2025
pulisher
May 07, 2025

3 Market-Beating Stocks with Solid Fundamentals - Yahoo Finance

May 07, 2025
pulisher
May 06, 2025

United Therapeutics (UTHR) Target Price Lowered by Argus, Retains Buy Rating | UTHR Stock News - GuruFocus

May 06, 2025
pulisher
May 05, 2025

Liquidia Fends Off Indication Challenge In UTC Tyvaso Fight - Law360

May 05, 2025
pulisher
May 05, 2025

United Therapeutics (UTHR) Receives Reiterated "Buy" Rating from HC Wainwright | UTHR Stock News - GuruFocus

May 05, 2025
pulisher
May 05, 2025

Liquidia Corporation: A Strong Buy On High Likelihood Of FDA Approval This Month - Seeking Alpha

May 05, 2025
pulisher
May 02, 2025

District Court Dismisses Dispute Filed by United Therapeutics Against Liquidia - GlobeNewswire Inc.

May 02, 2025
pulisher
May 02, 2025

US judge dismisses United Therapeutics' counterclaims over Liquidia's 'Yutrepia' - MLex

May 02, 2025
pulisher
May 02, 2025

United Therapeutics (UTHR) Gets a Hold from Wells Fargo - The Globe and Mail

May 02, 2025
pulisher
May 02, 2025

Legal Victory: Liquidia Clears Major Hurdle for YUTREPIA Dual-Indication Approval This Month - Stock Titan

May 02, 2025
pulisher
May 01, 2025

BofA raises United Therapeutics stock target to $321 - Investing.com Australia

May 01, 2025
pulisher
May 01, 2025

United Therapeutics (UTHR): Morgan Stanley Raises Price Target | - GuruFocus

May 01, 2025
pulisher
May 01, 2025

BofA raises United Therapeutics stock target to $321 By Investing.com - Investing.com Canada

May 01, 2025
pulisher
May 01, 2025

United Therapeutics (UTHR) Analyst Update: JP Morgan Maintains R - GuruFocus

May 01, 2025
pulisher
May 01, 2025

United Therapeutics (UTHR) Analyst Update: JP Morgan Maintains Rating | UTHR Stock News - GuruFocus

May 01, 2025
pulisher
May 01, 2025

United Therapeutics (UTHR): Morgan Stanley Raises Price Target | UTHR Stock News - GuruFocus

May 01, 2025
pulisher
May 01, 2025

Decoding United Therapeutics Corp (UTHR): A Strategic SWOT Insig - GuruFocus

May 01, 2025
pulisher
May 01, 2025

United Therapeutics Corporation (NASDAQ:UTHR) Q1 2025 Earnings Call Transcript - Insider Monkey

May 01, 2025
pulisher
May 01, 2025

Avepoint, Meta, United Therapeutics - TradingView

May 01, 2025
pulisher
May 01, 2025

United Therapeutics: Q1 Earnings Snapshot - New Haven Register

May 01, 2025
pulisher
May 01, 2025

United Therapeutics Corp (UTHR) Q1 2025 Earnings Call Highlights: Record Revenue and Strategic ... - Yahoo Finance

May 01, 2025
pulisher
May 01, 2025

United Therapeutics Reports Strong Q1 2025 Growth - TipRanks

May 01, 2025
pulisher
Apr 30, 2025

United Therapeutics Corp. Reports Record Revenue Growth - TipRanks

Apr 30, 2025
pulisher
Apr 30, 2025

Earnings call transcript: United Therapeutics Q1 2025 beats expectations - Investing.com

Apr 30, 2025
pulisher
Apr 30, 2025

United Therapeutics Corp Surpasses Q1 2025 Estimates with $7.18 EPS and $794.4 Million Revenue - GuruFocus

Apr 30, 2025
pulisher
Apr 30, 2025

United Therapeutics (UTHR) Surpasses Q1 Earnings Expectations - GuruFocus

Apr 30, 2025
pulisher
Apr 30, 2025

United Therapeutics beats Q1 estimates, shares edge higher - Investing.com

Apr 30, 2025
pulisher
Apr 30, 2025

United Therapeutics Q1 Earnings, Revenue Rise - marketscreener.com

Apr 30, 2025
pulisher
Apr 30, 2025

United Therapeutics Q1 2025 slides: revenue jumps 17%, organ transplant milestone nears - Investing.com

Apr 30, 2025
pulisher
Apr 30, 2025

United Therapeutics Corporation Reports First Quarter 2025 Financial Results - TradingView

Apr 30, 2025
pulisher
Apr 30, 2025

UNITED THERAPEUTICS Corp SEC 10-Q Report - TradingView

Apr 30, 2025

United Therapeutics Corp Stock (UTHR) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
drug_manufacturers_specialty_generic RDY
$14.28
price down icon 0.35%
$119.12
price down icon 1.19%
drug_manufacturers_specialty_generic HCM
$13.27
price up icon 0.38%
$8.50
price up icon 0.24%
$16.94
price up icon 2.36%
Cap:     |  Volume (24h):